ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NGNE vs PBYI // FORWARD P/E MULTIPLE

Neurogene Inc. (NASDAQ) VS. Puma Biotechnology Inc (NASDAQ) • 15-METRIC TALLY: NGNE 2 — PBYI 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NGNE VS. PBYI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NGNE PBYI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 74.50% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 29.30% -64.30 PBYI /roic <GO>
EV/EBITDA & P/E Valuation — 13.8x — TIE /valuation <GO>
Free Cash Flow Yield -13.59% 7.67% -21.26 PBYI /fcf-yield <GO>
Operating Margin — 16.30% — TIE /operating-margins <GO>
Net Profit Margin — 13.60% — TIE /net-margins <GO>
Revenue Growth (YoY) — -0.90% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 12.76 0.20 +12.56 NGNE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 8/9 -6.00 PBYI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.6 52.6 -2.00 PBYI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — 16.3x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $551.3M $538.9M $12.4M NGNE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NGNE REV PBYI REV NGNE GROSS % PBYI GROSS % NGNE FCF PBYI FCF
FY 2025 $289.3M $228.4M — 74.5% -$78.4M $41.7M
FY 2024 $925.0K $230.5M — 72.1% -$71.4M $38.9M
FY 2023 $155.6M $235.6M — — -$51.4M $27.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NGNE // BETA —
PBYI // BETA —